BMO’s Evan David Seigerman: Novo Nordisk CEO departure reflects disparity with Eli Lilly

Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC’s ‘Money Movers’ to discuss reactions to the departure of Novo Nordisk’s CEO, what is means for the company’s trajectory, and more.